

AMENDMENTS TO THE CLAIMS

The below listing of pending claims is provided for the Examiner's convenience.

Claims 1-23 (Canceled)

Claim 24 (Previously Presented): A replication-defective recombinant bovine adenovirus (BAV) expression vector comprising a bovine adenovirus genome with a deletion of all or part of the E1 region;

said expression vector further comprising an insertion, at the site of the deletion, of a non-BAV nucleotide sequence under the control of an effective promoter.

Claim 25 (Previously Presented): The recombinant BAV expression vector of claim 24 further comprising a deletion of part or all of the E3 region.

Claim 26 (Previously Presented): The recombinant BAV expression vector of claim 25 comprising an insertion at the site of the E3 deletion, of one or more non-BAV nucleotide sequences, said non-BAV nucleotide sequences being under the control of one or more effective promoters.

Claim 27 (Previously Presented): The replication-defective recombinant BAV expression vector of claim 24 wherein the non-BAV nucleotide sequence is a mammalian sequence.

Claim 28 (Previously Presented): The replication-defective recombinant BAV expression vector of claim 24 wherein the non-BAV nucleotide sequence is a human sequence.

Claim 29 (Previously Presented): A method for introducing and expressing a non-BAV nucleotide sequence in a mammalian cell, wherein the method comprises contacting said mammalian cell with the replication-defective recombinant BAV expression vector according to claim 24.

Claim 30 (Previously Presented): A method for introducing and expressing a non-BAV nucleotide sequence in a mammalian cell, wherein the method comprises contacting said mammalian cell with the replication-defective recombinant BAV expression vector according to claim 26.

Claim 31 (Previously Presented): The method according to claim 29, wherein the non-BAV nucleotide sequence is a mammalian sequence.

Claim 32 (Previously Presented): The method according to claim 29, wherein the non-BAV nucleotide sequence is a human sequence.

Claim 33 (Previously Presented): The vector of claim 24 wherein said BAV is BAV subgroup 1.

Claim 34 (Previously Presented): A replication-defective recombinant bovine adenovirus (BAV) comprising a bovine adenovirus subgroup 1 genome with a deletion of part or all of the E1 multiple gene coding region, said deletion being replaced by a heterologous nucleotide sequence coding for a polypeptide produced by a disease causing organism or an antigenic determinant produced by a disease causing organism, wherein said heterologous nucleotide sequence is in association with an effective promoter.

Claim 35 (Previously Presented): The recombinant BAV of claim 34 further comprising a deletion of part or all of E3.

Claim 36 (Previously Presented): A method for eliciting an immune response in a mammalian host to protect against an infection comprising administering a vaccine composition comprising,

(a) a replication-defective recombinant BAV of claim 34 wherein the heterologous nucleotide sequence encodes an antigenic determinant produced by a disease organism; and

(b) a pharmaceutically acceptable excipient.

Claim 37 (Previously Presented): A vaccine for protecting a mammalian host against infection comprising:

(a) a replication-defective recombinant BAV of claim 34 wherein the heterologous nucleotide sequence encodes an antigenic determinant produced by a disease organism; and

(b) a pharmaceutically acceptable excipient.

Claim 38 (Previously Presented): A replication-defective recombinant bovine adenovirus vector (BAV) comprising a bovine adenovirus subgroup 1 genome wherein part or all of the E1 multiple gene coding region and part or all of the E3 multiple gene coding region are deleted and a heterologous nucleotide sequence encoding a foreign protein or fragment thereof is inserted into at least one of the deletions.

Claim 39 (Previously Presented): The vector of claim 34 which is a bovine adenovirus type 3.

Claim 40 (Previously Presented): The vector of claim 38 which is a bovine adenovirus type 3.

Claims 41-42 (Canceled)